Trial Profile
Clinical study of Apatinib combination with SOX as First line treatment in patients with adenocarcinoma of the Stomach or Gastroesophageal Junction
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2017
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 07 Nov 2017 New trial record